Mice deficient in the transcriptional repressor B-cell CLL/lymphoma 6 (Bcl6) exhibit similar T helper 2 (T H 2) immune responses as patients with allergic diseases. However, the molecular mechanisms underlying Bcl6-directed regulation of T H 2 cytokine genes remain unclear. We identified multiple Bcl6/STAT binding sites (BSs) in T H 2 cytokine gene loci. We found that Bcl6 is modestly associated with the BSs, and it had no significant effect on cytokine production in newly differentiated T H 2 cells. Contrarily, in memory T H 2 (mT H 2) cells derived from adaptively transferred T H 2 effectors, Bcl6 outcompeted STAT5 for binding to T H 2 cytokine gene loci, particularly Interleukin4 (Il4) loci, and attenuated GATA binding protein 3 (GATA3) binding to highly conserved intron enhancer regions in mT H 2 cells. Bcl6 suppressed cytokine production epigenetically in mT H 2 cells to negatively tune histone acetylation at T H 2 cytokine gene loci, including Il4 loci. In addition, IL-33, a pro-T H 2 cytokine, diminished Bcl6's association with loci to which GATA3 recruitment was inversely augmented, resulting in altered IL-4, but not IL-5 and IL-13, production in mT H 2 cells but no altered production in newly differentiated T H 2 cells. Use of a murine asthma model that generates high levels of pro-T H 2 cytokines, such as IL-33, suggested that the suppressive function of Bcl6 in mT H 2 cells is abolished in severe asthma. These findings indicate a role of the interaction between T H 2-promoting factors and Bcl6 in promoting appropriate IL-4 production in mT H 2 cells and suggest that chronic allergic diseases involve the T H 2-promoting factor-mediated functional breakdown of Bcl6, resulting in allergy exacerbation. . GATA binding protein 3 (GATA3), a key regulator of T H 2 cell differentiation, subsequently facilitates T H 2 cytokine gene transcription in T H 2 cells (3, 4) . In mice and humans, IL-4 is a key cytokine in T H 2 response initiation and IgE isotype class switching (5), whereas IL-5 and IL-13 are important in focal inflammation in allergic settings (5) . The generation of lineage-committed effector T H cells peaks within approximately 1 wk. Some of the effectors will survive and become long-lived memory cells. T H 2 effector cells can become memory T H 2 (mT H 2) cells (6) , which are likely to be involved in maintaining allergic pathogenesis, although the regulatory mechanisms in these cells remain unclear.
The protooncogene B-cell CLL/lymphoma 6 (Bcl6) is a sequence-specific transcriptional repressor (7, 8) . Increased T H 2 cytokine production has been observed after ex vivo T-cell stimulation in Bcl6-KO mice. We previously reported that Bcl6 repressed Il5 expression (9) . However, the molecular mechanisms underlying Bcl6-directed regulation of T H 2 cytokine genes remain unclear. Bcl6-binding DNA sequences resemble the IFN-γ-activated sequence motif bound by STAT proteins (10) , suggesting that Bcl6 represses T H 2 cytokine gene expression via competitive binding against STAT factors in T H 2 cytokine gene loci (7) . However, T H 2 cell differentiation was not influenced by the absence of Bcl6 under T H 2-skewing conditions (11) . Additionally, T H 1 cell differentiation was similar between WT and Bcl6-KO cells under T H 1-skewing conditions (11) . Conversely, the differentiation of T-follicular helper (T FH ) cells is believed to result from Bcl6-mediated suppression of differentiation to other T H cell lineages (12) (13) (14) . Conversely, we showed that excess exogenous Bcl6 in T cells suppressed T H 2 cytokine production in a murine model of chronic pulmonary inflammation (15) . Therefore, considerable uncertainty surrounds the molecular mechanisms by which Bcl6 regulates T H 2 cell differentiation and cytokine production.
Recent studies recognized nonlymphoid-derived cytokines [thymic stromal lymphopoietin (TSLP), IL-25, and IL-33] as integral factors in promoting T H 2-type responses; however, their pathophysiological Significance It has been suggested that the transcriptional repressor Bcl6 suppresses T helper 2 (T H 2) immune responses underlying allergic diseases. However, the molecular role of B-cell CLL/lymphoma 6 (Bcl6) in T H 2 cells is incompletely understood in pathophysiological settings. We found that Bcl6 suppressed cytokine production in memory T H 2 cells through binding to intron 2 of the Interkeukin 4 (Il4) locus using murine models. Furthermore, IL-33 controlled Bcl6 function at the chromatin level and consequently, augmented cytokine production in memory T H 2 cells. Therefore, pro-T H 2 cytokines, such as IL-33, play a role in chronic allergic diseases via the functional breakdown of Bcl6. This study identifies a relationship between T H 2-promoting factors and Bcl6 in T H 2 cells, which may lead to therapeutic strategies against chronic allergic diseases.
roles in mT H 2 cells are incompletely understood. The IL-33 receptor is expressed on T H 2 and innate immune cells, including basophils, mast cells, eosinophils, and type 2 innate lymphoid cells (16) (17) (18) . In vitro-differentiated T H 2 cells are also activated to produce IL-5 and IL-13 but not IL-4 in response to IL-33, regardless of T-cell receptor (TCR) engagement (19, 20) . Accordingly, IL-33 may regulate cellular functions in allergic diseases by cross-linking innate and adaptive immune responses. For example, IL-33 administration to WT mice induces T H 2 cytokines in the lungs. This pro-T H 2 inflammatory effect appears independently of the adaptive immune response because mice deficient in the recombinase-activating gene 2 (RAG2) develop a comparable response to IL-33 (21) . Exogenous IL-33 can enhance allergen-nonspecific IgE Ab production in naïve WT mice by inducing IL-4 production mainly in innate cells (22) . However, treatment with an Ab against ST2, an IL-33 receptor subunit (23) , largely abrogated allergic airway inflammation and reduced antigen-specific IgE Ab and T H 2 cytokine production in a murine ovalbumin (OVA)-immunized allergy model. IL-33 does not induce IL-4 production in newly differentiated T H 2 cells (19, 20) , and whether it induces the same in mT H 2 cells is uncertain.
In this study, we found that Bcl6 down-regulates T H 2 cytokine gene expression in mT H 2 cells. Furthermore, the findings of this study indicate that T H 2 cytokine gene regulation mediated by T H 2-promoting factors, such as IL-33, is associated with modulated Bcl6 function in mT H 2 cells, resulting in allergic exacerbation via enhanced T H 2 cytokine production.
Results
Role of Bcl6 in Cytokine Production. To investigate the role of Bcl6 in T H 2 cell differentiation and in vitro and in vivo maintenance, cultured naïve CD4 + T cells were stimulated with antigen under T H 2-skewing conditions and expanded with IL-2 until day 7 or sequentially maintained with IL-7 for 28 d to yield T H 2 cells of in vitro early-phase (EP) or late-phase (LP) postdifferentiation types [T H 2 early-phase cells (T H 2EPs) and T H 2 late-phase cells (T H 2LPs), respectively]. T H 2EPs were also adoptively transferred into BALB/c WT mice to generate mT H 2 cells in vivo. T cellintrinsic Bcl6 expression did not affect T H 2EP differentiation (Fig.  1A) . However, the frequency of IL-4 + WT T H 2LPs was decreased compared with that of Bcl6-KO T H 2LPs (Fig. 1A) . Il4, Il5, and Il13 mRNA expression levels were similar between Bcl6-KO and WT T H 2EPs, whereas their levels, particularly Il4 and Il5, in Bcl6-KO T H 2LPs were significantly higher than those in WT cells (Fig. 1B ). Bcl6-KO mT H 2 cells also exhibited augmented T H 2 cytokine production at the mRNA and protein level compared with WT mT H 2 cells (Fig. 1) . However, the mRNA expression levels of Gata3 in T H 2EPs, T H 2LPs, and mT H 2 cells were similar between Bcl6-KO and the WT, whereas their levels were decreased over time after T H differentiation (Fig. S1A) . According to T H 1 function, IFN-γ production was not significantly affected by Bcl6 at any T H 2-cell phase (Fig. 1A) , and the mRNA levels of the T H 1 transcription factor Tbox protein expressed in T cells (T-bet) in both T H 1 and T H 2 cells were constant between Bcl6-KO and the WT (Fig. S1B ).
Bcl6-Mediated Histone Modification at T H 2 Cytokine Gene Loci. To investigate chromatin modification at Bcl6/STAT (BS) binding regions [IL5BS (9) and putative BSs] (Fig. S2A) , we analyzed the acetylation levels of histone H3 (Ac-H3) at lysines (K9 and K14), which are known to play important roles in transcriptional activation and chromatin assembly at T H 2 cytokine gene loci in T H 2 cells at different phases using a ChIP assay ( Fig. 2A) . Bcl6-KO and WT T H 2EPs exhibited similar Ac-H3 levels, with particularly high levels at the Il4 intron 2 region. Compared with Bcl6-KO cells, WT T H 2LPs displayed decreased Ac-H3 levels at each BS, excluding IL5BS, IL13BS, BS1, and BS2, and promoter regions of Il4 (Il4p), Il5p, and Il13p. These decreased levels in WT T H 2LP cells were rescued after Bcl6 inhibition ( Fig. 2A) . A ChIP assay (Fig. 2B) revealed modest Bcl6 binding to each region in WT T H 2EPs; conversely, binding of STAT5 rather than STAT6 was observed at each BS in both WT and Bcl6-KO cells. In all cultures, STAT5 associated with the T H 2 locus control region (LCR) and Il4 intron 2 but not with BS1 and BS2. In WT T H 2LPs, broad Bcl6 binding was observed from IL5BS to BS7 (excluding IL13BS, BS1, and BS2), particularly at Il4 intron 2 (BS3-S6), whereas STAT5 binding was lower in WT cells than in Bcl6-KO cells. GATA3 binding was observed at each major GATA (G) binding region [G1 in Il5p (24), G2 in Rad50 hypersensitive site 7 in T H 2LCR, CGRE upstream of the proximal Il13p (25), G3 in Il4 intron 2 (26), G4 in HS5a (24) , and G5 in conserved noncoding sequence 2 (CNS2) (Fig. 2C , Upper and Fig. S2B) ], similar to WT and Bcl6-KO T H 2EPs. GATA3 binding was completely attenuated in both WT and Bcl6-KO T H 2LPs compared with in T H 2EPs (Fig. 2C) . Whereas GATA3 predominantly associated with G3 among G sites in both WT and KO cells in all cultures, GATA3 binding was significantly greater in Bcl6-KO T H 2LPs than in WT cells. Regarding mT H 2 cells, Ac-H3 levels, and Bcl6, STAT5 and GATA3 binding to T H 2 cytokine gene loci resembled the findings in T H 2LPs (Fig. S2 C-E ). Therefore, in T H 2LPs and mT H 2 cells, Bcl6 seems to directly outcompete STAT5 and indirectly attenuate GATA3 binding to T H 2 cytokine gene loci. To investigate the effect of Bcl6 on the level of corresponding transcriptional regulators for chromatin remodeling, we examined T H 2EPs and T H 2LPs from WT, Bcl6-KO, and Bcl6-transgenic (Bcl6-TG) mice. Intracellular staining (Fig. S3A ) and Western blotting (Fig. S3B ) revealed similar levels of critical activators, including GATA3 and phosphorylated STAT5 (pSTAT5), regardless of Bcl6 levels at each culture phase. Notably, the pSTAT5 + population of T H 2EPs is mainly included in the GATA3-expressing population and present at a similar ratio in WT and Bcl6-KO mice, regardless of IL-33 and/or TCR restimulation. T H 2LPs exhibited no significant GATA3 + population but consistently expressed some pSTAT5, regardless of the Bcl6 genotype. Notably, GATA3 protein expression levels were similar between WT and Bcl6-KO T H 2LPs after restimulation (Fig. S3A ). Bcl6 protein levels had no apparent changes at each culture phase in WT and TG cells (Fig. S3B ).
Dampening of Bcl6-Mediated Suppressor Activity by an Intron Enhancer in the Il4 Locus. We focused on the Il4 intron 2 region, wherein Bcl6/ STAT5 strongly associates with multiple sites in mT H 2 cells. The DNA sequences of this 222-bp region, which included BS3 and G3, are highly conserved between mice and humans and designated as the highly conserved intron enhancer (hcIE) (Fig. 3A) . The hcIE was included in DNase I hypersensitive sites (HS)2 (1.2 kbp), at which G3 was identified as a critical regulatory region for GATA3 binding-mediated Il4 expression in a study of HS2-KO mice (26) . To examine the role of hcIE, we generated hcIE-KO mice ( Fig. S4 ) and observed markedly diminished IL-4 production in both hcIE-KO T H 2EPs and T H 2LPs compared with that in WT cells. Notably, hcIE-KO T H 2EPs and T H 2LPs also displayed reduced, albeit partially reduced, IL-5 and IL-13 production relative to WT cells, even in the presence of abundant exogenous All results are representative of (A) six or (B and C) seven independent experiments with similar outcomes. ND, not detected. *P < 0.05; **P < 0.01. Fig. 3B) . In T H 2EPs, increased Bcl6 binding and decreased STAT5 binding at Il5, Rad50, and Il4 intron 2 (BS4-BS6) and decreased GATA3 binding at Il5, Rad50, Il13, and CNS2 were widely observed across the T H 2 cytokine gene loci when hcIE was abolished ( Fig. 3 C and D) . The differences in transcriptional factor binding dwindled between WT and hcIE-KO T H 2LPs. Because Bcl6 binding was augmented in hcIE-KO T H 2 cells, hcIE may dampen this Bcl6-mediated suppressor activity. In fact, 
IL-4 (
, (E) n = 6-8, or (F) n = 6-7 samples in each experiment. ND, not detected; NS, not significant. *P < 0.05; **P < 0.01.
T H 2 cytokine gene expression, excluding Il4, was significantly restored in hcIE-KO T H 2EPs and T H 2LPs as well as in WT T H 2LPs after Bcl6 inhibitor treatment (Fig. 3E ). In accordance with gene expression, Ac-H3 levels at Il5p and Il13p (except at Il4p) and those at various BSs (excluding Il13BS, BS1, and BS2) were distinctly reduced in hcIE-KO T H 2EPs compared with those in WT T H 2EPs (Fig. 3F) . The reduced Ac-H3 levels were significantly restored in hcIE-KO T H 2EPs after Bcl6 inhibitor treatment, although this inhibitor had less effect on the residual intron 2 region relative to other sites. The Bcl6 mRNA expression level in WT mT H 2 cells but not in WT T H 2LPs cells was slightly elevated compared with that in WT T H 2EPs, whereas the level in each T H 2 cell type was constant, regardless of hcIE function (Fig. S5) . Therefore, hcIE is critical for chromatin remodeling of T H 2 cytokine gene loci in T H 2 cells through the regulation of Bcl6-mediated suppressor activity.
Association Between IL-33 and Bcl6 in T H 2 Cells. The T H 2-promoting cytokine IL-33 is known to induce IL-5 and IL-13, but not IL-4, production in T H 2 cells (19, 20) . We confirmed this effect of IL-33 on T H 2EPs (Fig. S6A) . Increased expression of ST2, an IL-33 receptor subunit, has been shown in ex vivo WT mT H 2 cells (27) , and we also confirmed augmented ST2 expression in WT T H 2LPs (Fig. S6B ) as well as WT mT H 2 cells (Fig. S6C ). The range of effective concentrations of IL-33 for inducing IL-4 in WT mT H 2 cells was wider than those of the other T H 2-promoting cytokines, namely TSLP and IL-25 (Fig. S6D) . TCR-restimulated IL-4 production was significantly reduced in Bcl6-TG mT H 2 cells compared with that in WT cells. In contrast, there was no significant difference in IL-4 production between WT and Bcl6-KO mT H 2 cells in the presence of IL-33 (Fig. 4) . To examine T H 2 phenotypes, T H 2 cells were simultaneously analyzed for ST2 and intracellular GATA3 expression levels. No significant differences were observed between the WT and Bcl6-KO for T H 2EPs and mT H 2 cells, regardless of IL-33 and/or TCR restimulation (Fig.  S6C) . Restimulation induced no apparent changes in ST2 expression or GATA3 protein levels in WT or Bcl6-KO T H 2EPs, whereas both ST2 expression and GATA3 expression levels were similarly increased in WT and Bcl6-KO mT H 2 cells after IL-33 and TCR restimulation. When we focused on the functional association between IL-33 and Bcl6 in mT H 2 cells, 30 ng/mL IL-33 augmented IL-4 production strongly in WT mT H 2 cells and modestly in Bcl6-KO mT H 2 cells (Fig. 4 A-C) and concomitantly, induced Il4 expression after TCR stimulation (Fig. 4D) . The effects of IL-33 on IL-5 ( Fig. 4C ) and IL-13 ( Fig. 4 A-C) production and their gene expression (Fig. 4D) were apparently observed in WT mT H 2 and Bcl6-KO cells. These effects of IL-33 on each T H 2 cytokine were similar in the cell types, although cytokine production was dominated by Bcl6-KO cells rather than WT cells in the absence of IL-33.
Effects of IL-33 on Bcl6-Mediated Histone Modification. Because differences in TCR-stimulated cytokine production between WT and Bcl6-KO mT H 2 cells were diminished by IL-33 pretreatment in a concentration-dependent manner, we hypothesized that IL-33 may exert its effect by attenuating the function of Bcl6. In WT mT H 2 cells, Bcl6 binding to BSs was reduced by exogenous IL-33 partially at 10 ng/mL and fully at concentrations exceeding 30 ng/mL (Fig. 5A, Upper) , at which histone acetylation within T H 2 cytokine gene loci resembled that in Bcl6-KO cells. Bcl6 mRNA expression did not significantly change in mT H 2 cells after IL-33 treatment (Fig. S6E) . Because GATA3 protein levels were minimal in T H 2LPs (Fig. S3) and mT H 2 cells (Fig. S6C) at rest in WT and Bcl6-KO mice, we examined GATA3 binding to these loci by IL-33, which induces Gata3 expression and/or phosphorylation and subsequent IL-5 and/or IL-13 production (27) .
Although the isolated WT mT H 2 cells displayed inferior GATA3 binding to the major sites compared with Bcl6-KO cells, IL-33 could significantly augment this binding (Fig. 5A , Lower) along with increases in histone acetylation at the responsible sites (Fig. 5B) to similar levels between Bcl6-KO and WT cells. The effects of IL-33 on histone acetylation within T H 2 cytokine gene loci occurred in a concentration-dependent manner. Bcl6 detaching and GATA3 binding were particularly associated with histone acetylation regarding T H 2 cytokine genes. Chromatin modification of Il5 occurred in response to IL-33 at lower concentrations than those observed for Il4 and Il13 in WT mT H 2 cells, indicating that regulation of Il5 is sensitive to IL-33 function among the gene foci. A maximum concentration of IL-33 broadly increased histone acetylation levels at BSs other than G sites to a similar extent in both WT and Bcl6-KO mT H 2 cells.
Because ERK-1-and ERK-2-mediated phosphorylation induces Bcl6 degradation (28), we hypothesized that IL-33-induced MAPK activation (19) is important for Bcl6-mediated decreases in T H 2 cytokine production in mT H 2 cells. In cultured T H 2LPs, ERK phosphorylation levels increased within 30 min of stimulation with 10 ng/mL IL-33; conversely, Bcl6 protein levels decreased to 10% of baseline, but they were restored in the presence of FR180204, which selectively inhibits ERK-1/2 activity (29) (Fig. 5C) . 
IMMUNOLOGY AND INFLAMMATION
IL-4, IL-5, and IL-13 production was increased by IL-33 in a concentration-dependent manner in WT and Bcl6-KO mT H 2 cells. In particular, IL-5 production levels in both cell types were remarkably similar in the presence of IL-33 at any concentration, and its production was not prevented by ERK inhibition. In WT mT H 2 cells, 10 ng/mL IL-33 slightly increased the production of IL-4 and IL-13, and their levels in WT cells approached those in KO cells. This effect of IL-33 was significantly suppressed by ERK inhibition in WT mT H 2 cells but not KO cells. A higher concentration of IL-33 (100 ng/mL) further augmented IL-4 and IL-13 production; meanwhile, their levels were not reduced by ERK inhibition, and they were similar between WT and Bcl6-KO mT H 2 cells (Fig. 5D ), indicating that IL-33 could introduce permissive chromatin modification of T H 2 cytokine genes via some critical functions, such as GATA3 activation, in addition to Bcl6 degradation.
Role of Bcl6 in the Effects of IL-33 Regarding an mT H 2 Cell-Mediated
Allergic Response. When Bcl6-KO or WT T H 2EPs on a DO11.10 background were adoptively transferred into naïve WT mice, we observed that Bcl6-KO mT H 2 cells exacerbated allergic airway inflammation with increases in T H 2 cytokine production and IgE Ab levels during the chronic phase (Fig. S7) . Accordingly, to examine the association between Bcl6 and high IL-33 levels, we modified our OVA model by simultaneously administering bacteria-derived LPSs, which are known to induce IL-33 production (30) (OVA-LPS model). When Il33-WT recipients were challenged with OVA or OVA plus LPS during the chronic phase, LPS augmented the OVA-induced recruitment of mT H 2 cells (Fig. S8A) and increase in IL-33 levels, which were much larger than those of IL-25 and TSLP (Fig. S8B) (Fig. 6A) . Expression of Il14, Il5, and Il13 was not different between WT mT H 2 and Bcl6-KO cells, although differences in Il4 expression in Bcl6-KO cells between Il33-KO and Il33-WT recipients were modest compared with those in WT cells (Fig. 6A) . Notably, in the presence of OVA alone, Il4 and Il13 expression was not affected by the presence of IL-33 (Fig. 6A, Middle) . Conversely, T H 2 cytokine levels in bronchial alveolar lavage fluid (BALF) were apparently increased in the OVA-LPS model for both genotypes of T H 2 cells compared with those in the OVA model (Fig. S8C) . However, contrary to the gene expression profile in MLNs, cytokine protein levels were not significantly affected by the absence of IL-33 in this model (Fig. S8C) . Finally, serum IgE levels were markedly increased to a similar extent among all Il33-WT recipients with WT or Bcl6-KO mT H 2 cells in the OVA-LPS model compared with those in the OVA alone model (Fig. 6B) certain settings. In this study, to focus on authentic mT H 2 cells, we analyzed WT BALB/c mice as a more representative physiological condition as opposed to nude mice (32) .
For STAT5, GATA3 is required for rapid histone acetylation at HS2 during early T H 2 cell differentiation (33). Zhu et al. (33) also showed that STAT5-induced chromatin accessibility at the T H 2 cytokine loci of T H 2 cells was augmented by GATA3 overexpression, indicating that GATA3 binding to G3 may support STAT5 binding to BSs in T H 2 cytokine loci and maintain the permissive chromatin remodeling of T H 2 cells. Therefore, STAT5 and GATA3 cooperate in permissive histone modification of the Il4 locus by binding to hcIE during T H 2 cell differentiation and memory development. GATA3 directly activates Il5p and Il13p but not Il4p (34, 35) . IL-5 and IL-13 production is completely lost after the conditional deletion of Gata3 after T H 2 cell lineage commitment (35) . However, the IL-4 production level is apparently reduced in these Gata3-deleted T H 2 cells, despite no change in IL-4 + cell frequency. Thus, hcIE may induce and maintain active chromatin structures of the Il4 locus to control the efficiency and rate of transcription by protecting them against epigenetic silencing, similar to a globin gene enhancer (36) . Accordingly, to induce chromatin activation effectively in the Il4 locus, STAT5-and GATA3-mediated epigenetic activity of hcIE may be induced in differentiating T H 2 cells by directly and/or indirectly protecting the Bcl6-mediated silencing, because Bcl6 binding was augmented in the absence of hcIE. Regarding the relationship with STAT5, Bcl6-binding DNA sequences resemble the IFN-γ-activated sequence motif bound by STAT proteins (10), suggesting that Bcl6 represses T H 2 cytokine expression via competitive binding against STAT factors in T H 2 cytokine gene loci (7), which results in a shift toward histone deacetylation. On the contrary, it is certain that Bcl6 reduces GATA3 binding based on data from the Bcl6-KO study. In T H 2LPs, GATA3 and pSTAT5 levels decreased, whereas Bcl6 protein levels remained nearly unchanged throughout the long-term culture period. Accordingly, during the memory phase, hcIE activity may be suppressed by Bcl6. However, uncertainty largely remains regarding the Bcl6-mediated machinery for GATA3 binding without changes in its gene expression. Therefore, additional studies are required in the future. Bcl6 might function in a concentration-dependent manner; however, we believe that the suppressor activity does not simply depend on its levels, because we observed that cytokine production by T H 2EPs derived from Bcl6-TG mice was not reduced compared with that in Bcl6-KO T H 2EPs (Fig. S10) . Dent et al. (37) also showed that Bcl6-KO T H 1 cells have no ability to produce T H 2 cytokines. Accordingly, we think that some activators (GATA3 and STATs) are essential for transcriptional processes in which the repressor activity of Bcl6 can be determined in functional balance with transcriptional activators, such as GATA3 and STATs. Therefore, in mT H 2 cells, Bcl6 properly tunes Il4 chromatin modification by preventing exaggerated activation of the gene, because it is strongly suggested that hcIE regulates chromatin remodeling at the Il4 locus by Bcl6 through direct competition with STAT5 and/or through indirect functional competition with GATA3. We previously reported that Bcl6 binds to Il5BS (9), also revealing that Il13 was regulated by Bcl6, despite the apparent lack of Bcl6 binding to IL13BS. However, histone acetylation levels at Il13p and GATA3 binding to CGRE were influenced by Bcl6 in mT H 2 cells. Regarding this result, Bcl6 might be involved in chromatin remodeling at the T H 2LCR, which positively affects the coordinated expression (38) of Il4 and Il13. Accordingly, Bcl6 seems to negatively regulate these genes by directly regulating the function of T H 2LCR, raising a query about the effects of hcIE on Il5 and Il13, because Bcl6 inhibitor treatment restored their expression levels in hcIE-KO T H 2 cells. Although there is a possibility of cooperative repression by Bcl6 via binding to hcIE for T H 2 cytokine gene foci, additional studies are required to investigate this obscure mechanism.
We investigated whether the function of Bcl6 is physiologically modified at the protein level in some pathological settings without gene manipulation, resulting in regulatory perturbation of T H 2 cytokine genes. Because ERK-phosphorylated Bcl6 is degraded by the ubiquitin-proteasome system (28), we observed a decrement of Bcl6 protein expression in mT H 2 cells in an IL-33-induced ERK-1/2 activation-dependent manner in vitro. As was observed in T H 2 cytokine production by mT H 2 cells, in which Bcl6 dissociated from target chromatin in the presence of IL-33, we hypothesized that the ERK signaling-mediated Bcl6 decrement might have a prominent role in cytokine gene regulation. Unfortunately, ERK inhibition did not reduce the IL-33-induced hyperproduction of T H 2 cytokines, such as IL-4, indicating that mT H 2 cell exposure to excess IL-33 reinforces permissive T H 2 cytokine gene modification by both decreasing Bcl6 protein levels and inducing GATA3, a representative IL-33-induced activator. In contrast, IL-33 augments the production of IL-5 and IL-13, but not IL-4, in T H 2EPs after TCR restimulation (19) , supporting the hypothesis that, in highly polarized T H 2 cells, intron 2 of the Il4 locus is completely opened by activated GATA3 before IL-33 exposure, which activates Il5 and Il13 but not Il4 by inducing GATA3 binding to the respective promoters. In addition to IL-33, IL-25 and TSLP are also known to induce T H 2 cytokine production via the expression of some critical transcriptional activators, such as Gata3, in T H 2 cells. Among the T H 2-promoting cytokines, we observed a wider range of effective concentrations of IL-33 than IL-25 and TSLP for inducing IL-4 in ex vivo WT mT H 2 cells. Because we observed that IL-33 exhibited a greater increase than IL-25 and TSLP in the OVA-LPS model, we expected IL-33 to play an important role in not only antagonizing Bcl6 function via protein degradation but also, inducing GATA3 for the activation of T H 2 cytokine genes, particularly Il4, in mT H 2 cells. Consistent with this finding, higher concentrations of IL-33 enhance the production of T H 2 cytokines, such as IL-4, in both WT and Bcl6-KO mT H 2 cells. These data imply that IL-33 at lower levels can function as an inducer by mainly suppressing Bcl6 via histone deacetylation; however, IL-33 at higher levels can function as a strong inducer via an additional function of activating GATA3. Conversely, in the presence of large amounts of Bcl6 (i.e., Bcl6-TG mT H 2 cells), TCR restimulation-induced IL-4 production was lower in Bcl6-TG mT H 2 cells; however, the inhibitory effect became moderate with increased IL-33 levels. Thus, Bcl6 could play an important role as an attenuator of hyperimmune response and inflammation against allergic pathology, whereas IL-33-induced functions could overcome Bcl6 activity in the highly severe pathology of asthma. In this pathology, IL-33 could induce robust inflammation with increases in IL-4 production and IgE serum levels, regardless of the presence of Bcl6 in the OVA-LPS model. These results indicate that Bcl6 functions as a repressor for the T H 2 cytokine production in the OVA model, whereas in the OVA-LPS model, IL-33 did more for the cytokine production in mT H 2 cells than alleviate BCL6-mediated suppression in a more severe allergy pathology. However, the possibility of there being other significant activating factors other than GATA3 for T H 2 response induction remains.
IL-4 should critically contribute to the development of allergic diseases, including asthma, because STAT6 phosphorylation in B cells is required for IgE class switching, depending on IL-4 in mice and either IL-4 or IL-13 in humans. In addition, Il4/Il13-KO mice exhibited completely abolished IgE production (39) . Recently, IL-4-producing T FH cells with low-level Gata3 expression were shown to induce IgE class switch recombination (CSR) by direct Ig class switching in the germinal center (GC), resulting in short-lived plasma cells producing low-affinity IgE Ab (40). Thus, transfer T H 2 cell-derived T FH cells might be involved in CSR to IgE. On the contrary, it has been reported that high-affinity memory IgG + B cells derived from GC migrate to the outer follicle and differentiate into high-affinity IgE + B cells via sequential Ig class switching with IL-4 (41). Furthermore, it has been suggested that IL-4 derived from T H 2 cells, rather than T FH cells, is critical at the outer follicle for sequential class switching for memory allergic responses (39).
When we examined OVA-specific Ab production in an allergic model (Fig. S11) , hcIE-KO mice, in which T FH cells could produce sufficient IL-4 similarly to WT mice (Fig. S11 A and B) , exhibited a normal memory response for IgG1 production after antigen challenge (Fig. S11C) . By contrast, IgE production, the primary response of which was not detected, was strikingly impaired in hcIE-KO mice after challenge (Fig. S11C) , supporting that IgE production is mainly conducted as a memory response depending on mT H 2 cells but not T FH cells. In addition, because Bcl6 is a critical master regulator for T FH cell differentiation, it is unlikely that Bcl6-KO T H 2 cells give rise to T FH cells that augment IgE production because of the impairment of T FH cell differentiation caused by deficiency of T cell-intrinsic Bcl6 (12) (13) (14) .
It is known that IL-33 induces innate cells to produce IL-4, leading to allergen-nonspecific IgE production and T H 2 cell differentiation (22) . However, the molecular mechanism by which IL-33 regulates cytokine production, in particular IL-4 production, by mT H 2 cells remains unclear. Our T H 2 cell transfer murine models showed that IL-33 is involved in the augmentation of IL-4 and antigen-specific IgE Ab levels by mT H 2 cells. However, the use of Il33-KO recipients in the OVA-LPS model illustrated a partial effect of IL-33 on both Bcl6-KO and WT mT H 2 cells in this severe asthma model. This result suggests that some unidentified mechanisms/factors, including IL-25 and TSLP, are also involved in the T H 2-promoting function in vivo. However, we propose that functional competition for epigenetic regulation via a balance between activation induced by T H 2-promoting factors, such as IL-33, and Bcl6-mediated suppression has enormous significance in the development of allergic diseases. Because some pathogenic bacteria contribute to the severity of asthma (42), the OVA-LPS model implies that the pathogenesis of chronic allergic diseases, particularly asthma and its exacerbation, is caused by the elevation of numerous risk factors, including IL-33 and IL-25. These factors may play an important role in conquering the protective function of Bcl6 against T H 2-type allergic immune responses.
Concerning the role of Bcl6 in the regulation of cytokine gene expression, we discovered a function of Bcl6 that directly regulates Il4 and Il5 and indirectly regulates Il13 at the chromatin level. We considered that Bcl6 physiologically promotes appropriate T H 2 cytokine production in mT H 2 cells and that functional balance between Bcl6 and activators may critically direct Il4 activation in particular. Such a function of Bcl6 could be involved in protection against the development of allergic disease. Because the repressor activity of Bcl6 must be influenced by activators, including GATA3 and STAT5, even in the presence of excess Bcl6, activators overcoming the repressor can induce Il4 expression. Therefore, we propose a mechanism whereby the interaction between T H 2-promoting factors and Bcl6 tunes T H 2 cytokine gene activation and contributes to the pathology of severe allergic diseases, and therefore, dampening of Bcl6 may be involved in the maintenance and exacerbation of chronic allergic pathogenesis. Thus, T H 2-promoting factors that suppress Bcl6 function may represent therapeutic targets for T H 2 cell-mediated disease.
Materials and Methods
Abs and Reagents. The Abs and reagents are described in SI Materials and Methods.
Mice. Bcl6-KO (43) and Bcl6-TG mice with exogenous Bcl6 under the control of the Lck proximal promoter (44) have been described previously. These mice were backcrossed with BALB/c mice more than 10 times. DO11.10-TG mice were purchased from The Jackson Laboratory. Il33-KO mice (45) have been described previously. hcIE-KO mice were generated at the Biomedical Research Center, Chiba University (SI Materials and Methods). All mice were used at 8-12 wk of age. All procedures conformed to the Chiba University Resolution on the Use of Animals in Research, and they were approved by the Institutional Animal Care and Use Committee at Chiba University School of Medicine. Mice were maintained under specific pathogen-free conditions in the animal center of Chiba University Graduate School of Medicine.
Purification of CD4 T Cells and Induction of T H Cells. Splenic naïve CD4 T cells and transferred T cells were isolated by a cell sorter (FACSVantage; BD Biosciences). Naïve T cells were stimulated for differentiation of T H 1 and T H 2 cells as previously described (11) . Details of the experimental methods are described in SI Materials and Methods.
FACS Analysis of Intracellular Cytokines. As previously described (11) , T H cells were restimulated for 6 h and treated with monensin (2 μM) for the last 3 h. After intracellular cytokine staining, cells were subjected to flow cytometric analysis. Details of the experimental procedure are described in SI Materials and Methods.
ChIP Assay. ChIP was performed as described previously (9) . Details of the experimental procedure are described in SI Materials and Methods.
mRNA Measurements. cDNA was synthesized from total RNA with the SuperScript III First-Strand Synthesis as described previously (9) . System (Invitrogen) was used for quantitative real-time RT-PCR (qRT-PCR) analysis. A list of primer sets used is included in SI Materials and Methods.
ELISA. The levels of IL-4 and IL-5 in culture supernatants or BALF were determined using a BD Cytometric Bead Array Kit (BD Biosciences). The levels of IL-13 and IL-33 in the samples were measured using ELISA kits (R&D Systems). Mouse IgE and IgG1 anti-OVA Abs were measured using assay kits (Chondrex). Specific absorbance was measured, and OD was quantified at 410 nM using a Multiskan JX Plate Reader (Thermo Lab System).
Western Blot Analysis. In vitro-differentiated T H 2 cells were subjected to the analysis. Details of the experimental procedure are described in SI Materials and Methods.
Analysis of Antigen-Induced Airway Inflammation. Details of the examination are described in SI Materials and Methods.
Statistical Analysis. Statistical significance was determined using Student's t tests (two-tailed) for two groups or one-way ANOVA (with Tukey's multiple comparisons tests) for three or more groups. P values <0.05 were considered significant.
